AB005. Assessing meaningful changes in disease activity as clinical trial clinical efficacy measures for cutaneous lupus erythematosus

To date, there are no approved treatments for cutaneous lupus erythematosus (CLE), a disease known to significantly burden a patient’s quality of life (QoL). Clinical trials are important for the advancement of treatments and outcome measures of these trials should reflect clinically meaningful impr...

Descripción completa

Detalles Bibliográficos
Autores principales: Chakka, Srita, Krain, Rebecca, Ahmed, Sarah, Concha, Josef Symon S., Feng, Rui, Werth, Victoria P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2021
Materias:
Abstract on Rheumatologic Skin Disease
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8033312/
http://dx.doi.org/10.21037/atm.2021.AB005

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8033312/
http://dx.doi.org/10.21037/atm.2021.AB005

Ejemplares similares